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ABSTRACT
Sheng Yu Decoction (聖愈湯 Shèng Yù Tang; SYD) is a popular traditional Chinese medicine (TCM) remedy used in treating cardiovascular 
and brain‑related dysfunction clinically; yet, its neuroprotective mechanisms are still unclear. Here, mice were subjected to an acute ischemic 
stroke to examine the efficacy and mechanisms of action of SYD by an integrated neurofunctional and transcriptome analysis. More than 
80% of the mice died within 2 days after ischemic stroke with vehicle treatment. Treatments with SYD (1.0 g/kg, twice daily, orally or 
p.o.) and recombinant thrombolytic tissue plasminogen activator (rt‑PA; 10 mg/kg, once daily, intravenously or i.v.) both significantly 
extended the lifespan as compared to that of the vehicle‑treated stroke group. SYD successfully restored brain function, ameliorated 
cerebral infarction and oxidative stress, and significantly improved neurological deficits in mice with stroke. Molecular impact of SYD by 
a genome‑wide transcriptome analysis using brains from stroke mice showed a total of 162 out of 2081 ischemia‑induced probe sets were 
significantly influenced by SYD. Mining the functional modules and genetic networks of these 162 genes revealed a significant upregulation 
of neuroprotective genes in Wnt receptor signaling pathway (3 genes) and regulation of cell communication (7 genes) and downregulation of 
destructive genes in response to stress (13 genes) and in the induction of inflammation (5 genes), cytokine production (4 genes), angiogenesis 
(3 genes), vasculature (6 genes) and blood vessel (5 genes) development, wound healing (7 genes), defense response (7 genes), chemotaxis 
(4 genes), immune response (7 genes), antigen processing and presenting (3 genes), and leukocyte‑mediated cytotoxicity (2 genes) by SYD. 
Our results suggest that SYD could protect mice against ischemic stroke primarily through significantly downregulating the damaging genes 
involved in stress, inflammation, angiogenesis, blood vessel formation, immune responses, and wound healing, as well as upregulating the 
genes mediating neurogenesis and cell communication, which make SYD beneficial for treating ischemic stroke.
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INTRODUCTION
Ischemic stroke is ranked as the leading common cause of death 
in developed countries, even though some drop in death rates has 
been reported.[1] Excitotoxicity is the major pathophysiological 
mechanism mediating ischemic stroke–induced brain injury by 
excessive glutamate accumulation in the extracellular space through 
which ionotropic N‑methyl‑D‑aspartate (NMDA) receptors in the 
brain are overactivated under stroke onset.[2,3] Excessive amount 
of glutamate excites neurons to death by inducing robust oxidative 
stress by overproduction of reactive oxygen and nitrogen species, 
such as hydroxyl radicals (OH−), superoxide anions (O2
.−), hydrogen 
peroxide (H2O2), nitric oxide (NO), and peroxynitrite (OONO
−).[3,4] 
The main free radical producing enzyme systems involved in‑
clude mitochondria, cyclooxygenase (COX), xanthine oxidase, 
gp91phox (NOX2), and inducible nitric oxide synthase (iNOS) in 
response to the activation of proinflammatory mediators (e.g., cy‑
tokines) produced by recruited leukocytes (e.g., neutrophils, mac‑
rophages, and T‑cells), active microglial cells, damaged neurons, 
and astrocytes in ischemic stroke–damaged tissues.[3,5] A key role 
for inflammatory cell activation in the development of ischemic 
stroke in humans has been highlighted.[6]
An inflammatory cascade is consequently activated in dam‑
aged tissue by ischemic stroke, leading to leukocyte infiltration 
and release of proinflammatory cytokines for amplification of 
inflammatory responses that mediate early blood–brain bar‑
rier (BBB) dysfunction following stroke.[7] Moreover, activation of 
inflammation‑related transcriptional factor(s) plays a pivotal role 
in mediating oxidative stress–induced cell injury and in regulat‑
ing post‑ischemic inflammation, possibly through upregulation 
of inflammatory genes and proteins that contribute to cell death 
in cerebral ischemia.[8,9] Although thousands of studies provide 
important evidence in understanding the pathophysiology of 
ischemic stroke at the cellular, molecular, and animal levels,[10,11] 
the recombinant thrombolytic tissue plasminogen activator (rt‑PA) 
has continued to be the only US Food and Drug Administra‑
tion (FDA)‑approved drug. According to clinical experience, 
rt‑PA is limited by its serious side effects, narrow therapeutic time 
window, and is suitable only for a limited group of patients with 
acute ischemic stroke.[12] Therefore, searching for drugs with more 
efficacy and lower toxicity from alternative and complementary 
medicine would be a practical and important therapeutic strategy 
for the treatment of ischemic stroke.
In traditional Chinese medicine (TCM), many formulas have 
clinically been used for treating stroke‑induced disability for cen‑
turies. As a classic TCM formula, Sheng Yu Decoction (聖愈湯 
Shèng Yù Tang; SYD) has been used for improving cardiovascular 
and neurological functional recovery in stroke‑induced disability in 
China.[13] Recent clinical study reported that integrative medicine 
using SYD together with Western medicine showed promising 
neuroprotective effects against ischemic stroke in 42 patients,[14] 
and also the protective effect of SYD on the apoptosis of neural 
cells after traumatic brain injury in rats.[15] However, how SYD 
could protect and improve neurological functions in ischemic 
stroke animals and the potential molecular mechanisms of action 
based on a genome‑wide view remain unclear.
In the present study, we investigated the protective effects and 
underlying molecular mechanisms of action of SYD, and compared 
it with a well‑known drug for stroke (i.e., rt‑PA) on animal survival 
rate, neurological functions, infarction volume, biochemical and 
the genome‑wild expression profiling in the transient focal cerebral 
ischemic mice brains.
MATERIALS AND METHODS
Preparation of SYD
Sheng Yu Decoction (聖愈湯 Shèng Yù Tang; SYD) was 
prepared using the method as given in our previous report[16] (men‑
tioned in supporting information) including microscopic examina‑
tion of the property of the crude drug and decoction pieces, molecu‑
lar sequence of internal transcribed spacer (ITS) region of the crude 
drug, and the high performance liquid chromatography (HPLC) 
fingerprint of each herb and whole remedy preparation. Briefly, 
the ingredients of SYD, i.e., Radix Rehmanniae (raw) (生地黃 
Shēng Dì Huáng), Radix Rehmanniae Preparata (熟地黄 Shóu 
Dì Huáng), Rhizoma Chuanxiong (川芎 Chuān Xiōng), Radix 
Ginseng (人參 Rén Shēn), Radix Angelicae Sinensis (當歸 Dāng 
Guī), and Radix Astragali membranaceus (黃耆 Huáng Qí), were 
mixed in order in the ratio 20:20:20:20:15:15 (dry weight). SYD 
was prepared by boiling with distilled water at 100°C for 30 min 
twice, and the drug solution was vacuum cool‑dried and made 
into drug powder and dissolved with distilled water to a final 
concentration of 2.0 g/ml (equivalent to the dry weight of the raw 
materials). The chemical fingerprint [Figure 1] was determined us‑
ing chromatographic separation carried out on a Thermo Syncronis 
C18 column (2.1 mm × 100 mm i.d., 1.7 μm) in Waters Acquity 
Figure 1. The representative chemical fingerprint of SYD product 
examined in this study. Chromatographic separation was carried out on a 
Thermo Syncronis C18 column (2.1 mm × 100 mm i.d., 1.7 μm) in Waters 
Acquity UPLC system with a diode array detector (DAD), monitored at 
210, 230, and 280 nm. The peak [5‑(hydroxymethyl) furfural] revealed 
at 3.4 min under 280 nm was used as a marker component. The mobile 
phase consisted of 0.1% phosphate water (A) and acetonitrile (B) using a 
gradient elution of 2% B at 0‑1 min, 2‑30% B at 1‑10 min, and 30‑70% B 
at 10‑15 min. The flow rate was 0.4 ml/min, and the column temperature 
was maintained at 35°C
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UPLC system equipped with a diode array detector (DAD), moni‑
tored at 230 nm. The mobile phase consisted of 0.1% phosphate 
water (A) and acetonitrile (B) using a gradient elution of 2% B 
at 0‑1 min, 2‑30% B at 1‑10 min, and 30‑70% B at 10‑15 min. 
The flow rate was 0.4 ml/min, and the column temperature was 
maintained at 35°C.
Animals and induction of ischemic stroke injury
All animal procedures and protocols were performed in ac‑
cordance with The Guide for the Care and Use of Laboratory 
Animals (NIH publication, 85‑23, revised 1996) and were reviewed 
and approved by the Animal Research Committee at National 
Research Institute of Chinese Medicine. Ischemic stroke injury 
in mice was induced as reported previously,[17] with some modi‑
fications (NRICM‑IACUC‑P‑99‑011). In brief, male imprinting 
control region (ICR) mice weighing 28‑32 g (National Labora‑
tory Animal Breeding and Research Center, Taipei, Taiwan) were 
anesthetized with a mixture of isoflurane (1.5‑2%), oxygen, and 
nitrogen. A fiberoptic probe was attached to the parietal bone, 
2 mm posterior and 5 mm lateral to bregma, and connected to a 
laser Doppler flowmeter (MBF3; Moor Instruments Ltd, Millwey, 
Axminster, UK) for continuous monitoring of cerebral blood 
flow (CBF). For the induction of ischemic stroke, right middle 
cerebral artery (RMCA) occlusion in mice was performed using 
a heat‑blunted monofilament surgical suture (6‑0, around 100 μm 
in diameter) which was inserted into the exposed external carotid 
artery, further advanced into the internal carotid artery, and wedged 
into the circle of Willis to obstruct the origin of the RMCA. The 
filament was left in place for 30 min and then withdrawn. Only 
animals that exhibited a reduction in CBF > 85% during RMCA 
occlusion and a CBF recovery by > 80% after 10 min of reperfusion 
were included in the study. This procedure leads to reproducible 
infarcts similar in size and distribution to those reported by others 
using transient RMCA occlusion of comparable duration.[17] Rec‑
tal temperature was monitored and kept constant (37.0 ± 0.5°C) 
during the surgical procedure and in the recovery period until the 
animals regained full consciousness. The experimental grouping 
was designed as described below. Additional animals (as indicated 
in each result) from the groups as described were used for other 
assays including analysis of survival rates, positron emission 
tomography (PET), free radical production in living mice, and 
transcriptome analysis.
Drug administration and animal grouping
The mice were randomly divided into the following 
groups (n = 20 in each group) including sham control, stroke, 
stroke + SYD (1.0 g/kg, p.o., twice daily), and stroke + 
rt‑PA (10 mg/kg, intravenously or i.v., once daily; Boehringer In‑
gelheim GmbH, Ingelheim am Rhein, Germany). Two hours after 
ischemic stroke induction, the mice were treated with SYD (p.o.) 
or rt‑PA (i.v.), or vehicle control distilled water (sham and stroke 
groups) daily. All animals were free to move and take food.
Assessment of neurological deficit scoring and analysis of 
survival rates
The neurological deficit of mice was determined just before 
the sacrifice on day 1 after stroke by analyzing their tracking 
distance and appearance of the typical behavior pattern (circling 
clockwise) related to ischemic stroke within 3 min in an observa‑
tion box (60 × 60 × 60 cm3) using a video‑tracking system soft‑
ware (SMART v2.5.21 Barcelona; Panlab, Spain). For survival rate 
analysis, mice were kept in isolators (individually ventilated cage 
systems) after stroke induction, given food and water ad libitum, 
and kept at 22 ± 2°C with alternating 12 h periods of light and 
dark. Survival rates were calculated immediately (day 0) and 
within 7 days after stroke induction.
Evaluation of infarct volume
Twenty‑four hours after ischemic reperfusion, the mice were 
sacrificed by rapid decapitation under deep anesthesia. The whole 
brain was rapidly removed. Immediately after being weighed, the 
brain was sliced into 2‑mm‑thick coronal sections and stained with 
2% 2,3,5‑triphenyltetrazoliumchloride (TTC, Sigma‑Aldrich, St 
Louis, MO, USA) for 30 min at 37°C in the dark, followed by 
fixation with 10% of formalin at room temperature (25°C) over‑
night. Brain slices lacking red staining defined the infarct area. The 
slices were photographed with a digital camera and analyzed by 
an image processing system (AlphaEaseFC 4.0; Alpha Innotech, 
San Leandro, CA, USA). Infarct volume was obtained according 
to the indirect method proposed by Swanson et al.[18] and corrected 
for edema by comparing the volume of ischemic and nonischemic 
hemispheres as described by Lin et al.[19] The infarct volume was 
expressed as mm3 of the whole brain volume.
A PET evaluation of the brain function
Cerebral glucose metabolism was measured to evaluate the 
brain function after stroke. Animals were injected with 100 μCi 
of 2‑deoxy‑2‑(F‑18) fluoro‑D‑glucose [(F‑18) FDG] and imaged 
on a small animal PET scanner (μPET; Concorde Microsystems, 
Knoxville, TN). Images were acquired for 10 min under inhala‑
tion anesthesia (isoflurane 2%). The level of radioactivity in brain 
tissue (percentage dose per gram) was estimated from the images 
according to the method published by Hsieh et al.[20]
Quantification of oxidative stress in living mice
Dihydroethidium (DHE; Molecular Probes, Eugene, OR, 
USA; 2.0 mg in 200 μl normal saline) was given i.v. to mice just 
before the onset of reperfusion for in vivo determination of free 
radical production in living mice. Reactive oxygen species (ROS) 
production was monitored at 24 h after reperfusion using the IVIS® 
Imaging System 50 Series (Xenogen Corp., Alameda, CA, USA) 
under 488‑nm excitation light. Living Image software (Xenogen 
Corp.) was used to analyze the bioluminescence in the brain. Data 
were expressed as photon flux in a region of interest (ROI). All the 
animals were imaged under inhalation anesthesia (isoflurane 2%). 
Signal intensities from ROIs were defined manually and expressed 
as photon flux (photons/sec/cm/sr), where steradian (sr) refers to 
the photons emitted from a unit solid angle of a sphere. Background 
photon flux was defined from an ROI of the same size drawn over 
the thorax of each animal, and these data were subtracted from the 
signal intensities measured the at sites of injury. Area under the 
curve (AUC) analyses were performed with AlphaEaseFC software 
(version 4.0; Alpha Innotech Corporation, San Leandro, CA, USA) 
and were expressed as the AUC of photon flux.
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Array data sets, array probe preparation, and data processing
Twenty‑four hours after induction of stroke, brains of sh‑
am‑operated control mice, ischemic stroke mice, and SYD‑treat‑
ed mice were subjected to total RNA extraction and microarray 
hybridization. In each group, the RNAs from six different mice 
were hybridized onto two different chips to have biological 
replica. The Affymetrix™ Mouse Genome 430 2.0 chips were 
used. Robust multi‑array analysis (RMA). log expression units 
were calculated from Affymetrix GeneChip array data using the 
“affy” package of the Bioconductor (http://www.bioconductor.
org/) suite of software for the R statistical programming lan‑
guage (http://www.r‑project.org/). The default RMA settings 
were used to background correct, normalize, and summarize all 
the expression values. Significant difference between sample 
groups was identified using the “limma” package of the Biocon‑
ductor. To control the multiple testing errors, a false discovery 
rate (FDR) algorithm was then applied to these P values to cal‑
culate a set of q‑values: Thresholds of the expected proportion of 
false positives, or false rejections of the null hypothesis. Heatmap 
was created by the dChip software (http://biosun1.harvard.edu/
complab/dchip/). Principal component analysis (PCA) was per‑
formed by the Partek Genomics Suite (http://www.partek.com/) 
to provide a visual impression of how the various sample groups 
were related. Gene annotation was performed by the ArrayFu‑
sion web tool (http://microarray.ym.edu.tw/tools/arrayfusion/). 
Gene Ontology (GO) database search were performed by the 
DAVID Bioinformatics Resources 6.7 interface (http://david.
abcc.ncifcrf.gov/).
Statistical analysis
All values in the text and figures are presented as the 
mean ± SEM. Data, except indicated, were analyzed by one‑way or 
two‑way analysis of variance (ANOVA) depending on the number 
of parameters for comparison, followed by post‑hoc Student–New‑
man–Keuls (SNK) t‑test for multiple comparisons.
RESULTS
Effects of SYD on survival rate and cerebral infarction after 
ischemic stroke
Most of the mice (>80%) died within 2 days after stroke 
induction with vehicle (distilled water) treatment, but treatment 
with SYD (1.0 g/kg, twice daily, p.o.) and rt‑PA (10 mg/kg, once 
daily, i.v.) both enhanced the survival rate as compared to ve‑
hicle (distilled water)‑treated stroke group. This was especially 
true on day 1 after stroke [Figure 2] (P < 0.05). The infarct volume 
induced by ischemic stroke on day 1 after stroke (60 ± 11 mm3, 
around 40% of the whole brain) was comparable with previous 
reports.[17] Treatment with SYD (1.0 g/kg) and rt‑PA significantly 
decreased the stroke‑induced cerebral infarction by 67% and 
43%, respectively [Figure 3] (P < 0.05). The hemodynamic 
and arterial blood gas measurements showed no significant dif‑
ferences before, during, or after the experiments among these 
groups (data not shown). Neurological deficit scoring was mea‑
sured on day 1 after stroke by determining the tracking distance 
within 3 min in a box; the distance (cm) of mice with ischemic 
stroke injury (510 ± 180) was significantly lower than those in the 
sham‑operated group (1510 ± 120) [Figure 4] (one‑way ANOVA, 
Figure 2. Protective effect of SYD on the survival rate in ischemic 
stroke‑injured mice within 7 consecutive days. Animal groups include 
sham, vehicle treated (stroke), SYD treated (1.0 g/kg, twice daily, p.o.; 
+SYD), and rt‑PA treated (10 mg/kg, daily, i.v.; +rt‑PA). Survival curves 
were computed using the Kaplan–Meier method. Differences in survival 
rates were assessed using the log‑rank test followed by Holm–Sidak 
method for all pairwise multiple comparisons. *P < 0.05 as compared to 
stroke group analyzed by one‑way ANOVA followed by SNK t‑test (n = 10 
for each group)
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Figure 3. Protective effect of SYD on cerebral infarction at 24 h after ischemic stroke. Animal groups include sham, vehicle treated (stroke), SYD 
treated (1.0 g/kg, twice daily, p.o., +SYD), and rt‑PA treated (10 mg/kg, daily, i.v., +rt‑PA). *P < 0.05 as compared to stroke group analyzed by one‑way 
ANOVA followed by SNK t‑test (n = 10 for each group). NA, data not available
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P < 0.05). Treatment with SYD and rt‑PA both significantly en‑
hanced the tracking distance (cm) to 1050 ± 160 and 800 ± 150, 
respectively [Figure 4] (one‑way ANOVA, P < 0.05). Besides, the 
typical neurological deficit behavior (circling clockwise) induced 
by ischemic stroke was significantly ameliorated by SYD and 
rt‑PA [Figure 4].
Effects of SYD on brain function and oxidative stress of 
living mice after stroke
To determine the neurofunctional effect of SYD, the brain 
image after stroke was examined by measuring the glucose 
metabolism in the brain of living mice using μPET imaging 
system. To determine the brain oxidative stress generated 
from free radical production, oxidative stress was monitored 
by DHE fluorescence in the brain of living mice using IVIS 
imaging system. In this study, ischemic stroke injury dramati‑
cally impaired glucose metabolism [Figure 5] and produced 
a large amount of free radical (as assayed by IVIS imaging) 
[Figure 6] in living mice, which may create enormous oxida‑
tive stress to damage brain tissues after stroke. Treatment with 
SYD and rt‑PA both significantly ameliorated brain function 
compromised by ischemic stroke [Figure 5]. SYD and rt‑PA 
both significantly reduced free radical production on day 1 after 
stroke [Figure 6].
Molecular impacts of SYD on ischemic mice brain
To provide more insight into the in vivo influences of SYD on 
ischemic mice brain, a genome‑wide transcriptome analysis was 
performed. A total of 162 out of 2081 ischemia‑influenced probe 
sets were found significantly reversed by the SYD using transcrip‑
tome analysis [Figure 7a]. A PCA plot using these 162 probe sets 
illustrated the differential gene expression patterns between dif‑
ferent mice groups. The gene expression pattern of SYD‑treated 
mice was closer to that of sham mice [Figure 7b]. On measuring 
the average linkage distances between mice transcriptomes and 
comparing with ischemic mice, SYD‑treated ones were found 
to be closer to sham controls [Figure 7c]. A heat map shows 64 
probe sets were commonly more abundant in SYD‑treated and 
sham mice, while another 98 ischemia‑induced probe sets were 
suppressed by SYD [Figure 7d]. The top 50 up‑ and downregulated 
genes are listed in Tables 1 and 2, respectively.
Figure 4. Protective effect of SYD on neurological deficit scoring at 24 h after ischemic stroke in live mice. Animal groups include sham, vehicle 
treated (stroke), SYD treated (1.0 g/kg, twice daily, p.o.; +SYD), and rt‑PA treated (10 mg/kg, daily, i.v.; +rt‑PA). Left panel: Representative neurological 
deficit scoring by determining the tracking distance and profiling within 3 min in a box, measured on day 1 after ischemic stroke. Right panel: Statistical 
analysis. †,*P < 0.05 as compared to sham or stroke group, respectively, analyzed by one‑way ANOVA followed by SNK t‑test (n = 3‑5 for each group)
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Figure 5. A representative μPET analysis of brain function (glucose 
metabolism) in live mice at 24 h after stroke. Animal groups include 
sham, vehicle treated (stroke), SYD treated (1.0 g/kg, twice daily, p.o., 
+SYD), and rt‑PA treated (10 mg/kg, daily, i.v., +rt‑PA). Arrows indicate 
ischemic brain areas for comparison
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Figure 6. IVIS imaging of free radical production in live mice at 24 h after stroke. Animal groups include sham, vehicle treated (stroke), SYD 
treated (1.0 g/kg, twice daily, p.o., +SYD), and rt‑PA treated (10 mg/kg, daily, i.v., +rt‑PA). Left panel: Representative IVIS imaging for free radical 
production; ROI, region of interest. Right panel: Statistical analysis. *P < 0.05 as compared to stroke group analyzed by one‑way ANOVA followed 
by SNK t‑test (n = 10 for each group). NA, data not available
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Table 1. The top 50 up‑regulated known genes in ischemic stroke mice treated with remedy SYD
Probe Set ID UniGene ID Gene title Gene symbol Location
1427371_at
1421024_at
1435417_at
1436258_at
1429190_at
1426336_at
1442707_at
1452453_a_at
1441572_at
1451751_at
1419581_at
1419845_at
1435494_s_at
1442279_at
1447204_at
1416658_at
1418533_s_at
1449113_at
1422542_at
1435708_at
1423259_at
1431229_at
1442341_at
1425870_a_at
1438450_at
1445928_at
1432432_a_at
1449494_at
1423331_a_at
1437214_at
1436767_at
1439830_at
1457813_at
1421163_a_at
1441634_at
1436780_at
1428484_at
1427620_at
1424701_at
1431074_a_at
1448673_at
1458539_at
1423343_at
1422751_at
1432130_a_at
1415694_at
1436485_s_at
Mm.439858
Mm.8684
Mm.27054
Mm.44841
Mm.300178
Mm.214994
Mm.131530
Mm.131530
Mm.167882
Mm.250841
Mm.27256
Mm.4543
Mm.355327
Mm.312133
Mm.341948
Mm.427436
Mm.36416
Mm.41715
Mm.391232
Mm.398608
Mm.458006
Mm.335715
Mm.441119
Mm.213204
Mm.268025
Mm.272185
Mm.390643
Mm.390643
Mm.328072
Mm.94135
Mm.276133
Mm.6595
Mm.287443
Mm.31274
Mm.39262
Mm.259191
Mm.44153
Mm.329076
Mm.128861
Mm.439910
Mm.328072
Mm.221041
Mm.284495
Mm.278444
Mm.275710
Mm.38433
Mm.300397
ATP‑binding cassette, sub‑family A (ABC1), member 8a
1‑acylglycerol‑3‑phosphate O‑acyltransferase 1 expressed 
sequence AI464131
Cdc42 guanine nucleotide exchange factor (GEF) 9
arylsulfatase B
calcium channel, voltage‑dependent, gamma subunit 7
calcium/calmodulin‑dependent protein kinase II alpha
calcium/calmodulin‑dependent protein kinase II alpha 
deleted in colorectal carcinoma
DNA‑damage‑inducible transcript 4‑like
discs, large homolog 4 (Drosophila) distal‑less homeobox 1, 
antisense desmoplakin
Enhancer of polycomb homolog 1 (Drosophila) Fibronectin 
leucine rich transmembrane protein 2 frizzled‑related 
protein
frizzled homolog 2 (Drosophila)
GC‑rich promoter binding protein 1‑like 1
G protein‑coupled receptor 34
Glutaminase
inhibitor of DNA binding 4
imprinted gene in the Prader‑Willi syndrome region
kalirin, RhoGEF kinase
Kv channel‑interacting protein 2
lin‑7 homolog A (C. elegans)
membrane‑associated ring finger (C3HC4) 6
RAB3C, member RAS oncogene family
RAB3C, member RAS oncogene
poliovirus receptor‑related 3
leucine rich repeat transmembrane neuronal 4
LUC7‑like 2 (S. cerevisiae)
mitogen‑activated protein kinase kinase kinase 5
Mitochondrial ribosomal protein S18A
nuclear factor I/A
netrin G1
O‑linked N‑acetylglucosamine (GlcNAc) transferase
oxysterol binding protein‑like 3
p53‑associated parkin‑like cytoplasmic protein 
protocadherin 20
phosphatidylinositol transfer protein, cytoplasmic 1
poliovirus receptor‑related 3
R3H domain 1 (binds single‑stranded nucleic acids)
solute carrier organic anion transporter family, member 1c1
transducin‑like enhancer of split 1, homolog of Drosophila 
E(spl)
tetratricopeptide repeat domain 14
tryptophanyl‑tRNA synthetase
whirlin
Abca8a
Agpat1
AI464131
Arhgef9
Arsb
Cacng7
Camk2a
Camk2a 
Dcc 
Ddit4l
Dlg4
Dlx1as
Dsp
Epc1
Flrt2
Frzb
Fzd2
Gpbp1l1
Gpr34
Gls
Id4
Ipw
Kalrn
Kcnip2
Lin7a
Mar6
Rab3c
Rab3c
Pvrl3
Lrrtm4
Luc7l2
Map3k5
Mrps18a
Nfia
Ntng1
Ogt
Osbpl3
Parc
Pcdh20
Pitpnc1
Pvrl3
R3hdm1
Slco1c1
Tle1
Ttc14
Wars
Whrn
chr11 E1
chr17 B1|17 18.7 cM
chr4 A5
chrX C3
chr13 C3‑D1|13 50.0 
cM
chr7 A1|7 2.0 cM
chr18 E1|18 33.0 cM
chr18 E1|18 33.0 cM
chr18 E2|18 45.0 cM
chr3 G3
chr11 B4
chr2 C2|2 44.0 cM
chr13 A3.3
chr18 A1 chr12 E
chr2 C3|2 49.75 cM
chr11 E1 chr4 C7 
chrX
A1.3
chr1 C1.1|1 25.9 cM
chr13 B|13 31.0 cM
chr7|7 28.0 cM
chr16 B3
chr19 D1|19 45.2 cM
chr10 D1
chr15 B2 chr13 D2.2
chr13 D2.2
chr16 B5 chr6 C3 
chr6 
B1
chr10 A3
chr17 C
chr4 C4‑C6|4 45.8 
cM
chr3 G1 
chrX D 
chr6 B3
chr17 C 
chr14 E1 
chr11 E1
chr16 B5 
chr1 E4 
chr6 G1
chr4 C3 
chr3 B 
chr12 F2
chr4 C1|4 31.4 cM
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Table 2. The top 50 down‑regulated genes in ischemic stroke mice treated with remedy SYD.
Probe Set ID UniGene ID Gene title Gene symbol Location
1419706_a_at
1451675_a_at
1448789_at
1417130_s_at
1460330_at
1457827_at
1425658_at
1419144_at
1449130_at
1427994_at
1424638_at
1460682_s_at
1417852_x_at
1417839_at
1448471_a_at
1452352_at
1419209_at
1425582_a_at
1417104_at
1448620_at
1425225_at
1457555_at
1420591_at
1435290_x_at
1417714_x_at
1422851_at
1425895_a_at
1418293_at
1440865_at
1427747_a_at
1421571_a_at
1449283_a_at
1418826_at
1423946_at
1435458_at
1452521_a_at
1424560_at
1422660_at
1418892_at
1439780_at
1424542_at
1421375_a_at
1419394_s_at
1448756_at
1428776_at
1417300_at
1442308_at
1417426_at
1424966_at
1451006_at
Mm.27481
Mm.302724
Mm.140988
Mm.196189
Mm.7214
Mm.317021
Mm.32955
Mm.37426
Mm.1894
Mm.277387
Mm.195663
Mm.439731
Mm.454553
Mm.22768
Mm.30144
Mm.439734
Mm.21013
Mm.27343
Mm.20829
Mm.22119
Mm.251254
Mm.186779
Mm.160369
Mm.235338
Mm.196110
Mm.157190
Mm.444
Mm.2036
Mm.276440
Mm.9537
Mm.458089
Mm.38343
Mm.436639
Mm.283968
Mm.328931
Mm.1359
Mm.2534
Mm.128512
Mm.27467
Mm.218533
Mm.3925
Mm.100144
Mm.21567
Mm.2128
Mm.7446
Mm.287187
Mm.340377
Mm.338790
Mm.29739
Mm.11223
A kinase (PRKA) anchor protein (gravin) 12 
aminolevulinic acid synthase 2, erythroid aldehyde 
dehydrogenase family 1, subfamily A3 angiopoietin‑
like 4
annexin A3 arylsulfatase J CD109 antigen CD163 
antigen CD1d1 antigen
CD300 antigen like family member F
cyclin‑dependent kinase inhibitor 1A (P21) CEA‑
related cell adhesion molecule 1 chloride channel 
calcium activated 1
claudin 5
cytotoxic T lymphocyte‑associated protein 2 alpha
cytotoxic T lymphocyte‑associated protein 2 beta
chemokine (C‑X‑C motif) ligand 1 endomucin
epithelial membrane protein 3
Fc receptor, IgG, low affinity III Fc receptor, IgG, 
low affinity IV G protein‑coupled receptor 151
G protein‑coupled receptor 84 histocompatibility 
2, class II antigen A, alpha hemoglobin alpha, adult 
chain 1
high mobility group AT‑hook 2 inhibitor of DNA 
binding 1
interferon‑induced protein with tetratricopeptide 
repeats 2
interferon induced transmembrane protein 6 
lipocalin 2
lymphocyte antigen 6 complex, locus C1
mitogen‑activated protein kinase 12
membrane‑spanning 4‑domains, subfamily A, 
member 6B
PDZ and LIM domain 2
proviral integration site 1
plasminogen activator, urokinase receptor
proline‑serine‑threonine phosphatase‑interacting 
protein 1
RNA binding motif protein 3
ras homolog gene family, member J
ribosomal protein L7‑like 1
S100 calcium binding protein A4
S100 calcium binding protein A6 (calcyclin)
S100 calcium binding protein A8 (calgranulin A)
S100 calcium binding protein A9 (calgranulin B)
solute carrier family 10, member 6
sphingomyelin phosphodiesterase, acid‑like 3B
SET and MYND domain containing 4 serglycin
transmembrane protein 40
xanthine dehydrogenase
Akap12
Alas2
Aldh1a3
Angptl4
Anxa3
Arsj
Cd109
Cd163
Cd1d1
Cd300lf
Cdkn1a
Ceacam1
Clca1
Cldn5
Ctla2a
Ctla2b
Cxcl1
Emcn
Emp3
Fcgr3
Fcgr4
Gpr151
Gpr84
H2‑Aa
Hba‑a1
Hmga2
Id1
Ifit2
Ifitm6
Lcn2
Ly6c1
Mapk12
Ms4a6b
Pdlim2
Pim1
Plaur
Pstpip1
Rbm3
Rhoj
Rpl7l1
S100a4
S100a6
S100a8
S100a9
Slc10a6
Smpdl3b
Smyd4
Srgn
Tmem40
Xdh
chr10 A1
chrX F3|X 63.0 cM
chr7 C
chr17 B1
chr5 E3|5 54.0 cM
chr3 G1
chr9 E1
chr6 F2
chr3 F1|3 48.0 cM
chr11 E2
chr17 A3.3|17 15.23 cM
chr7 A3|7 5.5 cM
chr3 H2‑H3|3 72.5 cM
chr16 A3|16 11.65 cM 
chr13 B2|13 36.0 cM 
chr12 C1|13
chr5 E‑F|5 51.0 cM
chr3 G3
chr7 B4|7 24.5 cM
chr1 H3|1 92.3 cM chr1 
H3|1 92.29 cM chr18 
B3
chr15 F3
chr17 B1|17 18.65 cM
chr11 A4|11 16.0 cM
chr10 D2|10 67.5 cM 
chr2 H1|2 84.0 cM 
chr19 C1
chr7 F5
chr2 A3|2 27.0 cM
chr15 D3
chr15 E3 chr19 B chr14 
D2
chr17 A3.3|17 16.4 cM
chr7 A3
chr9 C
chrX A1.1|X 2.0 cM
chr12 C3
chr17 C
chr3 F1‑F2|3 43.6 cM 
chr3 F1‑F2|3 43.6 cM 
chr3 F1‑F2|3 43.6 cM
chr3 F1‑F2|3 43.6 cM
chr5 E5
chr4 D2.3
chr11 B5 chr10 B4 
chr6 E3
chr17 E2|17 45.3 cM
Coordinated changes of functional modules in SYD‑treated 
mice
We next organized SYD‑affected genes into functional groups 
for having better insight into the biological consequences of gene 
expression changes. According to the GO database, SYD treatment 
significantly enriched genes involved in the regulation of cell 
communication and Wnt receptor signaling pathway (P = 0.01 and 
0.04, respectively) [Table 3]. Seven genes related to the regulation 
of cell communication and three Wnt receptor signaling pathway 
genes were specifically induced in the brains of ischemic mice 
by SYD [Table 3]. Among the SYD‑downregulated genes, genes’ 
response to stress (13 genes, enrichment P value = 0.0015), wound‑
ing (7 genes, enrichment P value = 0.0021), inflammation (5 genes, 
P = 0.0110), development of vasculature (6 genes, P = 0.0027) 
and blood vessel (5 genes, P = 0.0145), angiogenesis (3 genes, 
P = 0.0130), defense response (7 genes, P = 0.0074), chemotaxis (4 
genes, P = 0.0086), immune response (7 genes, P = 0.0094), 
cytokine production (4 genes, P = 0.0165), antigen processing 
and presentation (3 genes, P = 0.0445), and leukocyte‑mediated 
cytotoxicity (2 genes, P = 0.0454) was reverted by SYD [Table 3]. 
The details of enriched GO categories, as well as the genes in‑
volved can be found in Tables 1‑3.
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DISCUSSION
Although SYD has been reported to be neuroprotective against 
brain injury in clinical and animal study,[13‑15] its mechanism of ac‑
tion based on a brain functional and a genome‑wide transcriptome 
analysis has not been revealed. Our results demonstrate for the first 
time that treatment with SYD (1.0 g/kg, p.o., twice daily) shows 
a protective effect against ischemic stroke in mice and signifi‑
cantly extends their survival rate and lifespan, as compared with 
vehicle‑treated ischemic stroke mice. The neuroprotective effect of 
SYD is effective up to at less 3 days after ischemic injury (around 
40% survival), and is more potent than rt‑PA in the improvement 
of neurological function, indicating that novel mechanism(s) or 
targets could be involved in the neuroprotective effects of SYD on 
ischemia‑induced brain injury. Here, we reveal the brain protec‑
tive effect of SYD in living mice that parallels with significant 
improvement in brain function (by PET imaging) and neurologi‑
cal deficits, as well as reduction of inflammation and oxidative 
stress (by IVIS imaging) without significant modulation of the 
hemodynamic, arterial blood gas, or physiological conditions.
The major pathological mechanisms leading to ischemic 
brain injury include ionic imbalance, oxidative/nitrosative stress, 
inflammatory responses, and apoptotic cell death, and all these 
mechanisms have been linked to excitotoxicity, an inappropriate 
activation of ionotropic NMDA receptors.[2,21] In this study, our 
results showed that ischemia induced a dramatic production of 
free radicals, which could be measured by oxidized DHE in living 
mice (by IVIS). Treatment with SYD dramatically reduced the 
oxidative stress and spared the tissue against ischemia‑induced 
brain infarction. An inflammatory cascade is initiated in the tissue 
damaged by free radicals, which leads to complement activa‑
tion (e.g.,C5a), firm adhesion molecule upregulation, microglial 
activation, leukocyte infiltration, chemotaxis, and release of pro‑
inflammatory cytokines that may amplify inflammation through 
activation of inflammatory signals (e.g., transcription factors) for 
induction of brain infarction.[4,22]
A pattern recognition analysis illustrated that SYD treat‑
ment reversed ischemia‑induced brain damage at a molecular 
level (162 genes reversed) [Figure 7]. Among these genes 
modulated by SYD, proinflammatory cytokine/chemokine re‑
ceptor, cytotoxic T lymphocyte–associated proteins and genes 
promoting inflammation, such as CxCl1, Fcgr3, Fcgr4, Ctla2a, 
Ctla2b, Ifit2, Ifitm6, CD109, CD163, CD1d1, and CD3001f, 
were suppressed by SYD. We showed for the first time by GO 
database‑based gene set enrichment analysis that SYD also 
upregulated a neuroprotective gene, camk2a, which is involved 
in the calcium signaling pathway. The gene product CaMKII 
is a member of calcium/calmodulin‑dependent kinase (CaMK) 
cascade, which is well‑established for its effects on modulating 
neuronal synaptic plasticity and learning and memory.[23] SYD 
also significantly potentiated the expression of a protective 
factor in the damaged area [e.g.,frizzled‑related protein (Frzb, 
alias Sfrp3), a secreted protein activating the Wnt survival and 
proliferating pathway, was induced by SYD] [Tables 1 and 3]. 
On the other hand, genes involved in wounding, stress, and 
acute inflammation were reverted by SYD [Table 3]. Leuko‑
cyte‑mediated cytotoxicity, immune response, and chemotaxis 
genes were all reduced after SYD treatment, implying the pre‑
vention of leukocyte infiltration in damaged regions, as well as 
Figure 7. Transcriptome analyses on ischemic stroke and SYD‑treated 
mice. (a) A Venn diagram illustrates there were 162 probe sets deregulated 
in ischemic stroke mice, but were rescued by the SYD treatment. (b) A PCA 
plot using the 162 probe sets. (c) Average linkage analysis using the above 
162 probe sets shows the relationships between sham, stroke‑induced, and 
SYD‑treated mice. (d) A heat map shows the upregulation (in red) and 
downregulation (in blue) patterns of the 162 probe sets
6KDPYV6WURNH6<'YV6WURNH 6WURNH 6<' 6KDP6<'6WURNH6KDP
$YHUDJHOLQNDJHGLVWDQFH WR6KDP6PLFH 6<'6WURNH
3& 3& d
c
b
a
Table 3. Functional module analysis for SYD‑induced neuroprotection 
in ischemic stroke mice.
SYD‑induced GO terms Count % P value
Regulation of cell communication 7 12.96296 0.010505
Wnt receptor signaling pathway 3 5.555556 0.040555
SYD‑repressed GO terms
Response to stress
Response to wounding 
Vasculature development 
Defense response 
Chemotaxis
Immune response 
Inflammatory response 
Regulation of angiogenesis 
Blood vessel development
Regulation of cytokine production 
Antigen processing and presentation 
Leukocyte mediated cytotoxicity
13
7
6
7
4
7
5
3
5
4
3
2
16.88312
9.090909
7.792208
9.090909
5.194805
9.090909
6.493506
3.896104
6.493506
5.194805
3.896104
2.597403
0.001596
0.002142
0.002744
0.007438
0.00861
0.009402
0.011088
0.013076
0.014564
0.016565
0.044586
0.045459
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Figure 8. SYD reverses 162 out of 2081 genes impaired by ischemic 
stroke to protect mice against ischemic stroke. Ischemic stroke damages 
neurons by triggering excitotoxicity through inducing strong inflammation 
and oxidative stress to damage BBB and neurons. SYD could protect 
mice against ischemic stroke primarily by significantly downregulating 
the genes involved in oxidative stress and strong inflammation, as well 
as by upregulating the genes mediating neurogenesis (Frzb/Wnt), which 
make SYD beneficial for ischemic stroke
,VFKHPLF6WURNH
%UDLQGDPDJH77&%UDLQG\VIXQFWLRQȝ3(7
([FLWRWR[LFLW\,QIODPPDWLRQ2[LGDWLYHVWUHVV0DVVIUHHUDGLFDOV,9,6%%%GDPDJH	/HDNDJHLQILOWUDWLRQ (QGRJHQRXV1HXURJHQHVLVHJ)U]E:QW 6<'6WURQJDFWLYDWLQJ6OLJKWDFWLYDWLQJ,QKLELWLQJNLOO UDVFXHVRXWRIJHQHVGDPDJHGE\LVFKHPLFVWURNH
the rescue of inflammation response and prevention of neuron 
cells from inflammation‑associated cell death. Furthermore, 
S100 calcium‑binding proteins (e.g.,S100a9) have been re‑
ported to display many proinflammatory functions and act as 
damage‑associated molecular pattern molecules.[24] Here, we 
observed that S100a4, S100a6, S100a8, and S100a9 were all 
significantly downregulated [Table 2], indicating that damaged 
BBB and inflammation could be compromised by SYD. Similar 
observation using DNA microarray chips containing 512 cDNA 
probe also identified S100a9 as one of the six potential targets 
downregulated by an effective TCM remedy.[25]
Angiogenesis genes such as vascular endothelial growth 
factor (VEGF) and its receptor Flk1 have been reported to be 
upregulated by an effective TCM remedy for stroke protection in 
rats on days 7‑14 after stroke.[26] In our array analysis, however, 
blood vessel and vasculature development as well as angiogenesis 
genes were less active in SYD‑treated mice [Tables 1 and 2]. 
This could be due to the upregulation of VEGF signaling, me‑
diating increased BBB permeability,[27] possibly by enhancing 
VEGF‑mediated activation of Rac‑1 caused free radical genera‑
tion,[28] and anti‑VEGF receptor antagonist (VGA1155) has been 
demonstrated to reduce infarction in rat permanent focal brain 
ischemia.[29] According to these observations, we propose that 
suppression of angiogenesis‑related pathways by SYD may be 
due to the fact that at the time point (day 1 after stroke) we har‑
vested brain RNA for transcriptome analysis, ischemia‑induced 
inflammatory responses, especially BBB leakage, may have 
been ameliorated by SYD in vivo, so blood vessel formation is 
no longer active in vivo.
In conclusion, our results reveal for the first time that the 
neuroprotective effect of SYD on ischemic stroke–induced brain 
injury in mice may depend on modulation of multiple molecular 
targets (162 genes) and pathways involved in the downregulation 
of stress, inflammation, immune response, and angiogenesis, as 
well as upregulation of neurogenesis‑related signals (Frzb/Wnt) 
and regulation of cell communication [Figure 8]. Our results pro‑
vide a possible explanation based on a genome‑wide transcriptome 
analysis integrated with neurofunctional assay, and the opportunity 
for the evaluation of SYD, a typical traditional Chinese medicine 
formula, in the treatment or combination therapy of cerebral 
ischemia–associated diseases.
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